The combination of duloxetine and bupropion for treatment-resistant major depressive disorder

Depression and Anxiety
George I PapakostasMaurizio Fava

Abstract

Our objective was to assess the effectiveness and safety of the combination of duloxetine and bupropion for treatment-resistant major depressive disorder (TRD). A retrospective chart review was conducted to identify patients with major depressive disorder (MDD) who had not experienced full remission of symptoms following an adequate trial of either duloxetine (n = 3) or bupropion (n = 7), and who then received the combination of these two antidepressants for TRD. Ten patients [37.2 +/- 11.3 years of age, five women, baseline Clinical Global Impressions (CGI) scale score 4.4 +/- 1.1], seven of whom had not remitted following treatment with bupropion (330 +/- 67 mg, 20.5 +/- 12.2 weeks), and three of whom had not remitted following treatment with duloxetine (90 +/- 30 mg, 18 +/- 2 weeks) received at least 4 weeks of combination treatment. The CGI was administered when the combination was first prescribed, and following 8.8 +/- 4.0 (range, 4-16) weeks of treatment. There was a significant decrease in CGI-S (Severity) scores (4.4 +/- 1.1 to 2.1+/-0.9, P <.0001) following combination treatment. Three (30%) patients were remitters at follow-up, and six (60%) were responders who did not achieve full symptom remission. The mean maximum...Continue Reading

References

Apr 1, 1997·The Journal of Clinical Psychiatry·J A BodkinR J Baldessarini
Jul 20, 2000·Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie·D MischoulonM Fava
Mar 7, 2001·The British Journal of Psychiatry : the Journal of Mental Science·M E ThaseR L Rudolph
Jan 25, 2003·Journal of Clinical Psychopharmacology·Charles DeBattistaAlan F Schatzberg
Jul 3, 2004·Journal of Clinical Psychopharmacology·David J GoldsteinMark A Demitrack

❮ Previous
Next ❯

Citations

May 26, 2012·Current Psychiatry Reports·Cássio M C BottinoSalma R I Ribeiz
Sep 4, 2012·Journal of Medicinal Chemistry·Younghue HanHoh-Gyu Hahn
Jun 17, 2014·Pharmacology, Biochemistry, and Behavior·Pravin Popatrao Kale, Veeranjaneyulu Addepalli
Dec 23, 2014·Expert Opinion on Investigational Drugs·Sheng-Min WangChi-Un Pae
Jun 1, 2011·Annals of Medicine·Eduard Vieta, Francesc Colom
Dec 6, 2011·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Stefano PorcelliAlessandro Serretti
Apr 22, 2010·CNS Neuroscience & Therapeutics·Mostafa El MansariPierre Blier
Nov 18, 2006·European Journal of Pharmacology·Amanda M ShawElliott Richelson
May 21, 2014·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Michele FornaroPantaleo Fornaro
Jun 30, 2014·Bioorganic & Medicinal Chemistry Letters·Jun YunHoh-Gyu Hahn
Jul 23, 2014·ACS Medicinal Chemistry Letters·Shuang LiuJohn E Macor
Jan 6, 2011·Clinical Neuropharmacology·Joseph BergmanVladimir Lerner
Jan 22, 2010·CNS Drugs·Richard C SheltonSara A Corya
Oct 22, 2011·Expert Review of Neurotherapeutics·Chi-Un PaeTae-Youn Jun
Mar 13, 2012·Pharmacological Reviews·Stephanie W WattsSusan M Barman
May 14, 2020·The International Journal of Neuropsychopharmacology·Rachael W TaylorAnthony J Cleare
Aug 31, 2016·Current Behavioral Neuroscience Reports·Dawn F Ionescu, George I Papakostas

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology
George I Papakostas
© 2021 Meta ULC. All rights reserved